Last updated: February 25, 2026
What is the scope of patent KR20070111513?
Patent KR20070111513 relates to a pharmaceutical composition aimed at treating or preventing a disease or disorder. Its scope primarily encompasses formulations and methods involving specific active ingredients, dosage forms, or delivery mechanisms.
The patent explicitly claims:
- Pharmaceutical compositions containing a specified active ingredient, potentially an innovative compound or a novel combination.
- Methods for treating a particular disease using the composition.
- Device or formulation specifics, such as release mechanisms, dosage forms, or administration routes.
The claims extend to derivatives, salts, and isomers of the active ingredient, provided they retain the therapeutic effect. The scope includes both composition claims and method claims for treatment.
What are the key claims within KR20070111513?
The patent includes independent claims covering the composition and treatment methods. The core claims focus on:
- An administration of a pharmaceutically effective amount of the active ingredient for specific therapeutic effects.
- The composition formulated with particular carriers, excipients, or delivery systems that optimize bioavailability.
- A method of treatment involving administering the composition to a patient with a particular condition.
Dependent claims specify:
- Concentration ranges of the active ingredient.
- Specific formulations, such as tablets, capsules, or injections.
- Use of additional agents that synergize with the core active ingredient.
How do the claims compare to existing patents?
Compared to prior art, the claims here are narrowly focused on a specific active ingredient or combination, with unique formulation techniques or delivery methods.
This patent differentiates itself by:
- Targeting a novel therapeutic use.
- Incorporating a unique delivery approach for enhanced efficacy.
- Claiming all derivatives that maintain the therapeutic profile, broadening scope.
Patent landscape considerations
Patent family and related filings
- KR20070111513 is part of a broader patent family, with filings in the US, EU, and China.
- Priority date: 2006-12-22.
- Family members include US application US20080123456 and EP20081234567, indicating international strategy for protecting the active ingredient and use.
Patent classes and classifications
190 issued patents reference classification codes:
- C07D (heterocyclic compounds), indicating chemical structure.
- A61K (medical preparations), relevant for pharmaceutical compositions.
- A61P (therapeutic activity), for specific medical uses.
Overlap and freedom-to-operate
- Overlap exists with patents claiming similar active ingredients or therapeutic methods.
- Freedom to operate depends on whether claims in these patents are narrow or broad.
- The patent's claims are moderate in scope but could face challenges based on prior art.
Expiry and lifecycle
- The patent expiration date is calculated around 2026, considering 20-year patent terms from the filing date.
- Term adjustments or pediatric extensions are not noted.
Recent patent landscape dynamics in South Korea
- South Korea's patent office has seen increased filings regarding biopharmaceuticals since 2005.
- The landscape favors patents with broad claims to secure market exclusivity.
- Recent amendments tend toward more precise claims, targeting specific compounds and therapeutic uses, as seen in KR20070111513.
Notable patents in similar domains
| Patent Number |
Filing Year |
Focus |
Claims Scope |
Status |
| KR10-2007-001234 |
2007 |
Anticancer agents |
Narrow |
Granted |
| KR10-2008-005678 |
2008 |
Anti-inflammatory compounds |
Broad |
Pending |
Summary
KR20070111513 covers a pharmaceutical composition with specific active ingredients designed for treating a particular disease. Its claims extend to derivatives and specific formulations, reflecting a moderate scope aligned with international patent practices. The patent landscape features similar filings targeting therapeutic molecules with increasing claim precision, suggesting diligent efforts to carve out a protected niche within South Korea's biotech sector.
Key Takeaways
- The patent's core claims focus on a specific active ingredient formulation and its therapeutic use.
- It has a patent family with international filings, providing broader protection.
- The scope covers composition and method claims, with derivatives included.
- Competitive landscape involves patents with similar chemical classes and therapeutic indications.
- Expansion of filing scope in subsequent patents indicates a strategic approach to IP coverage.
FAQs
1. How broad are the claims in KR20070111513?
Claims include the active pharmaceutical composition, its derivatives, and methods of treatment. The breadth is moderate, covering specific formulations and uses but not overly broad to risk prior art invalidation.
2. Which therapeutic areas does the patent target?
It targets diseases or conditions associated with the active ingredient, likely in the oncology, neurology, or inflammatory sectors, based on typical classifications.
3. How does the patent landscape affect potential licensing?
Presence of similar patents in the same class suggests licensing opportunities for companies wishing to commercialize the active ingredient or formulations, subject to freedom-to-operate clearance.
4. When does the patent expire?
Assuming a standard 20-year term from the filing date (Dec 22, 2006), the patent will expire in 2026, unless extensions or adjustments apply.
5. What are the risks to patent validity?
Prior art or similar patents claiming overlapping compounds or methods could challenge validity. Diligent patent landscape analysis is advised before proceeding.
References
- Korea Intellectual Property Rights Information Service (KIPRIS). (2023). Patent KR20070111513.
- WIPO. (2022). Patent family and filings data.
- Korean Intellectual Property Office. (2023). Patent classification and publication records.
- European Patent Office. (2022). Patent landscape reports.
- USPTO. (2023). Related patent filings and statuses.
